Technology Transfer. Upon written request of Apellis, [[Bachem CH:Organization]] shall promptly (within no more than ​ following receipt of such request) initiate transfer to Apellis in writing of all technical information related to the Manufacture of Drug Substance pursuant to this Agreement, including, but not limited to, information concerning ​ under this Agreement. Apellis shall be entitled to use and ​ the Drug Substance or Product. Apellis agrees to ​ transfer including, but not limited to, ​. Upon written request by Apellis, [[Bachem CH:Organization]] shall ​ pursuant to this Agreement, including information concerning ​. To the extent that ​ pursuant to this Section 9.4 to be ​, Apellis shall ​ and the Parties shall ​.

At any time upon the request of Client ​ of a Product Agreement for any reason, Patheon will provide assistance as reasonably requested by Client to transfer part or all of Client’s manufacturing process, know-how and analytical testing methodology for the Product to Client or Client’s third-party designee (“Technology Transfer”) to assist Client to manufacture the Product. Patheon will ensure that the Technology Transfer is performed on its behalf by personnel skilled in providing the Manufacturing Services. The Technology Transfer will include provisions of the master batch record all other documents, information and knowledge as necessary or appropriate to transfer work performed as part of the Manufacturing Services by Patheon and may include reasonable consultation, meetings and travel to another site. Patheon will also disclose to Client any Patheon Intellectual Property that is reasonably required to manufacture the Product and grant to Client an irrevocable, fully paid, sublicensable license to exploit the Patheon Intellectual Property as reasonably required to manufacture the

Technology Transfer. Promptly following the Effective Date, ITEOS shall transfer and deliver to GSK (in order to enable GSK to practice under the licenses granted to GSK under Section 9.1 (License Grant to GSK)), Know-How within the ITEOS Technology (including Materials) to enable GSK to Develop, Manufacture and Commercialize Licensed Antibodies and Licensed Products as contemplated under this Agreement.

Technology Transfer. Upon successful completion of the Development Plan and pilot scale in Phase III, the initial tech transfer to Licensee will occur with each party bearing their own costs and Licensor shall transfer the Production Strain(s) and sufficient know-how and Confidential Information to enable Licensee to use the Production Strains to develop and commercialize the Product(s) in the Field. If additional support is requested, Licensee shall pay for Licensor’s time and expenses in transferring the Production Strains and related Technology at Licensor’s standard full-time equivalent (“FTE”) rates for Licensor personnel having the knowledge and experience to affect the transfer. During the additional technology transfer and as needed thereafter, Licensee shall reimburse Licensor’s costs to # ship samples and Production Strains; # provide technical support to enable Licensee to grow the Production Strains to produce the Product; and # expenses and costs for related travel, if applicable.

Technology Transfer. Upon completion of the FIM Study and exercise by Cell Medica of its option under Sections 3.1 or 3.2, Baylor shall transfer to Cell Medica all Technology in Baylor’s possession or control, to the extent not already in Cell Medica’s possession, relating to the Future Oncology Invention or Future Non-Oncology Invention (each, an “Invention”) and/or Trigger Oncology Product or Trigger Non-Oncology Product, as the case may be (each, a “Trigger Product”) for which such option was exercised, including all Technology relating to the Trigger Product (if the option is so exercised) and any Future Product which embodies, includes or incorporates, or is made using, such Invention (if the option to such Invention is exercised). In addition, Baylor will provide # reasonable assistance and cooperation in order to enable Cell Medica or its designee to implement and utilize such transferred Technology, # provide Cell Medica with access to Baylor’s employees and contractors with appropriate expertise to answer Cell Medica’s questions related to such transfer; and # to Cell Medica or its designee its inventory of such Future Product and in-process materials (if any) if applicable.

Technology Transfer. The Parties expressly agree that they shall work together to transfer the Manufacturing Process to the Facility, including implementing the technology transfer plan set forth in Project Plan. Customer shall fully support such technology transfer as reasonably requested by [[Lonza:Organization]].

Technology Transfer. NVCR shall use good faith efforts to, within ​ days of the Effective Date, provide and transfer to Zai the NVCR Know-How which shall be that exists on the Effective Date and was not previously provided to Zai (the “Initial Technology Transfer”). Thereafter, during the Term, NVCR shall # at each meeting of the JSC (and, in any event, on a quarterly basis if any JSC meeting is not held in a particular Calendar Quarter), provide Zai with a summary of additional NVCR Know-How (if any) developed or included in the License and details of any Product Updates and Product Improvements developed ​, # transfer any such NVCR Know-How and Product Updates to Zai ​, and # provide Zai with reasonable access to NVCR personnel involved in the research and Development of Licensed Products, either in person at NVCR’s facility or by teleconference (the “Continuing Technology Transfer,” and together with the Initial Technology Transfer, the “Technology Transfer”). Thereafter, during the Term, at JSC meetings, NVCR shall keep Zai reasonably informed of NVCR’s Development activity as it relates to Zai’s Development and Commercialization in the Territory. For the avoidance of doubt, NVCR personnel shall not be obligated to travel to Zai’s facilities, and NVCR’s transfer obligations under this Section 4.1 shall apply solely to the extent the NVCR Know-How is reasonably necessary to support Zai’s Development and Commercialization of the Licensed Product in the Field in the Territory in accordance with this Agreement.

Technology Transfer. For each Therapeutic Program, within ​ of the Manufacturing Transition Initiation Date, the JMT shall draft and approve a Technology Transfer Plan. As promptly as possible following the JMT’s approval of the Technology Transfer Plan for a Therapeutic Program, Poseida, ​, shall initiate and complete (and cause its Authorized Subcontractors to initiate and complete) a transfer to Roche, or its designee, to the extent not previously disclosed (including under [Section 5.3]), and in accordance with the applicable Technology Transfer Plan for such Therapeutic Program, as described in this [Section 5.4]. The transfer obligations described in [Sections 5.4.1, 5.4.2, and 5.4.3]3]3] collectively, the “Technology Transfer”:

. Promptly following the Effective Date, [[DURECT:Organization]] shall provide electronic copies to INNOCOLL, for no additional consideration or cost reimbursement for the non-physical transfer, of all:

Technology Transfer.The Parties shall make their personnel available at the Facility to the extent reasonably necessary to enable their transfer and implementation activities in accordance with the PSA. Client shall transfer to SBL the Reference Standards, Client Technology, Client Materials, and Cell Line to SBL in accordance with the plan, timelines and quantities set forth in the PSA, which